<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28273839</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>04</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>01</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Mar</Month>
              <Day>04</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Parkinson's Disease: From Pathogenesis to Pharmacogenomics.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">551</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms18030551</ELocationID>
        <Abstract>
          <AbstractText>Parkinson's disease (PD) is the second most important age-related neurodegenerative disorder in developed societies, after Alzheimer's disease, with a prevalence ranging from 41 per 100,000 in the fourth decade of life to over 1900 per 100,000 in people over 80 years of age. As a movement disorder, the PD phenotype is characterized by rigidity, resting tremor, and bradykinesia. Parkinson's disease -related neurodegeneration is likely to occur several decades before the onset of the motor symptoms. Potential risk factors include environmental toxins, drugs, pesticides, brain microtrauma, focal cerebrovascular damage, and genomic defects. Parkinson's disease neuropathology is characterized by a selective loss of dopaminergic neurons in the substantia nigra pars compacta, with widespread involvement of other central nervous system (CNS) structures and peripheral tissues. Pathogenic mechanisms associated with genomic, epigenetic and environmental factors lead to conformational changes and deposits of key proteins due to abnormalities in the ubiquitin-proteasome system together with dysregulation of mitochondrial function and oxidative stress. Conventional pharmacological treatments for PD are dopamine precursors (levodopa, l-DOPA, l-3,4 dihidroxifenilalanina), and other symptomatic treatments including dopamine agonists (amantadine, apomorphine, bromocriptine, cabergoline, lisuride, pergolide, pramipexole, ropinirole, rotigotine), monoamine oxidase (MAO) inhibitors (selegiline, rasagiline), and catechol-<i>O</i>-methyltransferase (COMT) inhibitors (entacapone, tolcapone). The chronic administration of antiparkinsonian drugs currently induces the "wearing-off phenomenon", with additional psychomotor and autonomic complications. In order to minimize these clinical complications, novel compounds have been developed. Novel drugs and bioproducts for the treatment of PD should address dopaminergic neuroprotection to reduce premature neurodegeneration in addition to enhancing dopaminergic neurotransmission. Since biochemical changes and therapeutic outcomes are highly dependent upon the genomic profiles of PD patients, personalized treatments should rely on pharmacogenetic procedures to optimize therapeutics.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cacabelos</LastName>
            <ForeName>Ramón</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>EuroEspes Biomedical Research Center, Institute of Medical Science and Genomic Medicine, 15165-Bergondo, Corunna, Spain. rcacabelos@euroespes.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>03</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059290" MajorTopicYN="N">Dopaminergic Neurons</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010597" MajorTopicYN="Y">Pharmacogenetics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071184" MajorTopicYN="Y">Pharmacogenomic Variants</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Atremorine</Keyword>
        <Keyword MajorTopicYN="N">Parkinson’s disease</Keyword>
        <Keyword MajorTopicYN="N">adrenaline</Keyword>
        <Keyword MajorTopicYN="N">antiparkinsonian drugs</Keyword>
        <Keyword MajorTopicYN="N">dopamine</Keyword>
        <Keyword MajorTopicYN="N">genomics</Keyword>
        <Keyword MajorTopicYN="N">growth hormone</Keyword>
        <Keyword MajorTopicYN="N">noradrenaline</Keyword>
        <Keyword MajorTopicYN="N">pharmacogenetics</Keyword>
        <Keyword MajorTopicYN="N">prolactin</Keyword>
      </KeywordList>
      <CoiStatement>The author is President of EuroEspes. </CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>1</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2017</Year>
          <Month>2</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>2</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>3</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>3</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28273839</ArticleId>
        <ArticleId IdType="pmc">PMC5372567</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms18030551</ArticleId>
        <ArticleId IdType="pii">ijms18030551</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Von Campenhausen S., Bornschein B., Wick R., Bötzel K., Sampaio C., Poewe W., Oertel W., Siebert U., Berger K., Dodel R. Prevalence and incidence of Parkinson’s disease in Europe. Eur. Neuropsychopharmacol. 2005;15:473–490. doi: 10.1016/j.euroneuro.2005.04.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.euroneuro.2005.04.007</ArticleId>
            <ArticleId IdType="pubmed">15963700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou Y.M., Liu J., Tian Z.Y., Lu D., Zhou Y.Y. Systematic review of the prevalence and incidence of Parkinson’s disease in the People’s Republic of China. Neuropsychiatr. Dis. Treat. 2015;15:1467–1472. doi: 10.2147/NDT.S85380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/NDT.S85380</ArticleId>
            <ArticleId IdType="pmc">PMC4474453</ArticleId>
            <ArticleId IdType="pubmed">26109861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muangpaisan W., Hori H., Brayne C. Systematic review of the prevalence and incidence of Parkinson’s disease in Asia. J. Epidemiol. 2009;19:281–293. doi: 10.2188/jea.JE20081034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2188/jea.JE20081034</ArticleId>
            <ArticleId IdType="pmc">PMC3924097</ArticleId>
            <ArticleId IdType="pubmed">19801887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirsch L., Jette N., Frolkis A., Steeves T., Pringsheim T. The Incidence of Parkinson’s Disease: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2016;46:292–300. doi: 10.1159/000445751.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000445751</ArticleId>
            <ArticleId IdType="pubmed">27105081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savica R., Grossardt B.R., Bower J.H., Ahlskog J.E., Rocca W.A. Time Trends in the Incidence of Parkinson Disease. JAMA Neurol. 2016;73:981–989. doi: 10.1001/jamaneurol.2016.0947.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2016.0947</ArticleId>
            <ArticleId IdType="pmc">PMC5004732</ArticleId>
            <ArticleId IdType="pubmed">27323276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pringsheim T., Jette N., Frolkis A., Steeves T.D. The prevalence of Parkinson’s disease: A systematic review and meta-analysis. Mov. Disord. 2014;29:1583–1590. doi: 10.1002/mds.25945.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.25945</ArticleId>
            <ArticleId IdType="pubmed">24976103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riedel O., Bitters D., Amann U., Garbe E., Langner I. Estimating the prevalence of Parkinson’s disease (PD) and proportions of patients with associated dementia and depression among the older adults based on secondary claims data. Int. J. Geriatr. Psychiatry. 2016;31:938–943. doi: 10.1002/gps.4414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/gps.4414</ArticleId>
            <ArticleId IdType="pubmed">26764603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moisan F., Kab S., Mohamed F., Canonico M., le Guern M., Quintin C., Carcaillon L., Nicolau J., Duport N., Singh-Manoux A., et al.  Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis. J. Neurol. Neurosurg. Psychiatry. 2016;87:952–957. doi: 10.1136/jnnp-2015-312283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2015-312283</ArticleId>
            <ArticleId IdType="pmc">PMC5013115</ArticleId>
            <ArticleId IdType="pubmed">26701996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cacabelos R.  World Guide for Drug Use and Pharmacogenomics. EuroEspes Publishing; Corunna, Spain: 2012. </Citation>
        </Reference>
        <Reference>
          <Citation>Cacabelos R., Cacabelos P., Torrellas C., Tellado I., Carril J.C. Pharmacogenomics of Alzheimer’s disease: Novel therapeutic strategies for drug development. Methods Mol. Biol. 2014;1175:323–556.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25150875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cacabelos R., Torrellas C., Carrera I. Opportunities in Pharmacogenomics for the treatment of Alzheimer’s Disease. Future Neurol. 2015;10:229–252. doi: 10.2217/fnl.15.12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/fnl.15.12</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cacabelos R., Torrellas C. Epigenetic drug discovery for Alzheimer's disease. Expert Opin. Drug Discov. 2014;9:1059–1086. doi: 10.1517/17460441.2014.930124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/17460441.2014.930124</ArticleId>
            <ArticleId IdType="pubmed">24989365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cacabelos R., Torrellas C. Epigenetics of aging and Alzheimer’s disease: Implications for pharmacogenomics and drug response. Int. J. Mol. Sci. 2015;16:30483–30543. doi: 10.3390/ijms161226236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms161226236</ArticleId>
            <ArticleId IdType="pmc">PMC4691177</ArticleId>
            <ArticleId IdType="pubmed">26703582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cacabelos R., Torrellas C., Teijido O., Carril J.C. Pharmacogenetic considerations in the treatment of Alzheimer’s disease. Pharmacogenomics. 2016;17:1041–1074. doi: 10.2217/pgs-2016-0031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/pgs-2016-0031</ArticleId>
            <ArticleId IdType="pubmed">27291247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katzenschlager R., Lees A.J. Treatment of Parkinson’s disease: Levodopa as the first choice. J. Neurol. 2002;249:II19–II24. doi: 10.1007/s00415-002-1204-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-002-1204-4</ArticleId>
            <ArticleId IdType="pubmed">12375059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cacabelos R. Parkinson’s disease: Old concepts and new challenges. Sci. Pages Alzheimers Dis. Dement. 2016;1:001.</Citation>
        </Reference>
        <Reference>
          <Citation>Cacabelos R., Fernández-Novoa L., Alejo R., Corzo L., Alcaraz M., Nebril L., Cacabelos P., Fraile C., Carrera I., Carril J.C. E-PodoFavalin-15999 (Atremorine®)-induced dopamine response in Parkinson’s Disease: Pharmacogenetics-related effects. J. Genom. Med. Pharmacogenom. 2016;1:1–26.</Citation>
        </Reference>
        <Reference>
          <Citation>Cacabelos R., Fernández-Novoa L., Alejo R., Corzo L., Rodríguez S., Alcaraz M., Nebril L., Cacabelos P., Fraile C., Carrera I., et al.  E-PodoFavalin-15999 (Atremorine®)-induced neurotransmitter and hormonal response in Parkinson’s Disease. J. Exp. Res. Pharmacol. 2016;1:1–12.</Citation>
        </Reference>
        <Reference>
          <Citation>Cacabelos R., Carrera I., Fernández-Novoa L., Alejo R., Corzo L., Rodríguez S., Alcaraz M., Nebril L., Casas A., Fraile C., et al.  Parkinson’s Disease: New solutions to old problems. EuroEspes J. 2017;11:74–96.</Citation>
        </Reference>
        <Reference>
          <Citation>Miller D.B., O’Callaghan J.P. Biomarkers of Parkinson’s disease: Present and future. Metabolism. 2015;64:S40–S46. doi: 10.1016/j.metabol.2014.10.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.metabol.2014.10.030</ArticleId>
            <ArticleId IdType="pmc">PMC4721253</ArticleId>
            <ArticleId IdType="pubmed">25510818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naughton C., O’Toole D., Kirik D., Dowd E. Interaction between subclinical doses of the Parkinson’s disease associated gene, α-synuclein, and the pesticide, rotenone, precipitates motor dysfunction and nigrostriatal neurodegeneration in rats. Behav. Brain Res. 2017;316:160–168. doi: 10.1016/j.bbr.2016.08.056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbr.2016.08.056</ArticleId>
            <ArticleId IdType="pubmed">27585560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ritz B.R., Paul K.C., Bronstein J.M. Of Pesticides and Men: A California Story of Genes and Environment in Parkinson’s Disease. Curr. Environ. Health Rep. 2016;3:40–52. doi: 10.1007/s40572-016-0083-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40572-016-0083-2</ArticleId>
            <ArticleId IdType="pmc">PMC5922777</ArticleId>
            <ArticleId IdType="pubmed">26857251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rokad D., Ghaisas S., Harischandra D.S., Jin H., Anantharam V., Kanthasamy A., Kanthasamy A.G. Role of Neurotoxicants and Traumatic Brain Injury in α-Synuclein Protein Misfolding and Aggregation. Brain Res. Bull. 2016 doi: 10.1016/j.brainresbull.2016.12.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainresbull.2016.12.003</ArticleId>
            <ArticleId IdType="pmc">PMC5623095</ArticleId>
            <ArticleId IdType="pubmed">27993598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toledo J.B., Arnold S.E., Raible K., Brettschneider J., Xie S.X., Grossman M., Monsell S.E., Kukull W.A., Trojanowski J.Q. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s Coordinating Centre. Brain. 2013;136:2697–2706. doi: 10.1093/brain/awt188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awt188</ArticleId>
            <ArticleId IdType="pmc">PMC3858112</ArticleId>
            <ArticleId IdType="pubmed">23842566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irwin D.J., Grossman M., Weintraub D., Hurtig H.I., Duda J.E., Xie S.X., Lee E.B., van Deerlin V.M., Lopez O.L., Kofler J.K., et al.  Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: A retrospective analysis. Lancet Neurol. 2017;16:55–65. doi: 10.1016/S1474-4422(16)30291-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(16)30291-5</ArticleId>
            <ArticleId IdType="pmc">PMC5181646</ArticleId>
            <ArticleId IdType="pubmed">27979356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen K.X., Miliç J., El-Khodor B., Dhana K., Nano J., Pulido T., Kraja B., Zaciragic A., Bramer W.M., Troup J., et al.  The Role of DNA Methylation and Histone Modifications in Neurodegenerative Diseases: A Systematic Review. PLoS ONE. 2016;11:e0167201.  doi: 10.1371/journal.pone.0167201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0167201</ArticleId>
            <ArticleId IdType="pmc">PMC5156363</ArticleId>
            <ArticleId IdType="pubmed">27973581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nussbaum R.L. Genentics of synucleopathies. Cold Spring Harb. Perspect. Med. 2017 doi: 10.1101/cshperspect.a024109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a024109</ArticleId>
            <ArticleId IdType="pmc">PMC5983162</ArticleId>
            <ArticleId IdType="pubmed">28213435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lill C.M. Genetics of Parkinson’s disease. Mol. Cell. Probes. 2016;30:386–396. doi: 10.1016/j.mcp.2016.11.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mcp.2016.11.001</ArticleId>
            <ArticleId IdType="pubmed">27818248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y., Feng H., Peng S., Xiao J., Zhang J. Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson’s disease: A meta-analysis. Neurosci. Lett. 2017;636:190–195. doi: 10.1016/j.neulet.2016.11.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neulet.2016.11.007</ArticleId>
            <ArticleId IdType="pubmed">27840145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olanow C.W., Brundin P. Parkinson’s disease and alpha synuclein: Is Parkinson’s disease a prion-like disorder? Mov. Disord. 2013;28:31–40. doi: 10.1002/mds.25373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.25373</ArticleId>
            <ArticleId IdType="pubmed">23390095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheffold A., Holtman I.R., Dieni S., Brouwer N., Katz S.F., Jebaraj B.M., Kahle P.J., Hengerer B., Lechel A., Stilgenbauer S., et al.  Telomere shortening leads to an acceleration of synucleinopathy and impaired microglia response in a genetic mouse model. Acta Neuropathol. Commun. 2016;4:87. doi: 10.1186/s40478-016-0364-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40478-016-0364-x</ArticleId>
            <ArticleId IdType="pmc">PMC4994259</ArticleId>
            <ArticleId IdType="pubmed">27550225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olszewska D.A., Fearon C., Lynch T. Novel gene (TMEM230) linked to Parkinson’s disease. J. Clin. Mov. Disord. 2016;3:17. doi: 10.1186/s40734-016-0046-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40734-016-0046-7</ArticleId>
            <ArticleId IdType="pmc">PMC5109748</ArticleId>
            <ArticleId IdType="pubmed">27872751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nuytemans K., Theuns J., Cruts M., van Broeckhoven C. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: A mutation update. Hum. Mutat. 2010;31:763–780. doi: 10.1002/humu.21277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/humu.21277</ArticleId>
            <ArticleId IdType="pmc">PMC3056147</ArticleId>
            <ArticleId IdType="pubmed">20506312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lardenoije R., Iatrou A., Kenis G., Kompotis K., Steinbusch H.W., Mastroeni D., Coleman P., Lemere C.A., Hof P.R., van den Hove D.L., et al.  The epigenetics of aging and neurodegeneration. Prog. Neurobiol. 2015;131:21–64. doi: 10.1016/j.pneurobio.2015.05.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pneurobio.2015.05.002</ArticleId>
            <ArticleId IdType="pmc">PMC6477921</ArticleId>
            <ArticleId IdType="pubmed">26072273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coppedè F. Genetics and epigenetics of Parkinson’s disease. Sci. World J. 2012 doi: 10.1100/2012/489830.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1100/2012/489830</ArticleId>
            <ArticleId IdType="pmc">PMC3353471</ArticleId>
            <ArticleId IdType="pubmed">22623900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernandez D.G., Reed X., Singleton A.B. Genetics in Parkinson’s disease: Mendelian versus non-Mendelian inheritance. J. Neurochem. 2016;139:59–74. doi: 10.1111/jnc.13593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jnc.13593</ArticleId>
            <ArticleId IdType="pmc">PMC5155439</ArticleId>
            <ArticleId IdType="pubmed">27090875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hill-Burns E.M., Ross O.A., Wissemann W.T., Soto-Ortolaza A.I., Zareparsi S., Siuda J., Lynch T., Wszolek Z.K., Silburn P.A., Mellick G.D., et al.  Identification of genetic modifiers of age-at-onset for familial Parkinson’s disease. Hum. Mol. Genet. 2016;25:3849–3862. doi: 10.1093/hmg/ddw206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddw206</ArticleId>
            <ArticleId IdType="pmc">PMC5216611</ArticleId>
            <ArticleId IdType="pubmed">27402877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y., Xu R. Phenome-based gene discovery provides information about Parkinson’s disease drug targets. BMC Genom. 2016;17:493.  doi: 10.1186/s12864-016-2820-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12864-016-2820-1</ArticleId>
            <ArticleId IdType="pmc">PMC5009520</ArticleId>
            <ArticleId IdType="pubmed">27586503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sandor C., Honti F., Haerty W., Szewczyk-Krolikowski K., Tomlinson P., Evetts S., Millin S., Keane T., McCarthy S.A., Durbin R., et al.  Whole-exome sequencing of 228 patients with sporadic Parkinson’s disease. Sci. Rep. 2017;7:41188. doi: 10.1038/srep41188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep41188</ArticleId>
            <ArticleId IdType="pmc">PMC5259721</ArticleId>
            <ArticleId IdType="pubmed">28117402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verstraeten A., Theuns J., van Broeckhoven C. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends Genet. 2015;31:140–149. doi: 10.1016/j.tig.2015.01.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tig.2015.01.004</ArticleId>
            <ArticleId IdType="pubmed">25703649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lill C.M., Roehr J.T., McQueen M.B., Kavvoura F.K., Bagade S., Schjeide B.M., Schjeide L.M., Meissner E., Zauft U., Allen N.C., et al.  Comprehensive research synopsis and systematic meta-analyses in Parkinson’s disease genetics: The PDGene database. PLoS Genet. 2012;8:e1002548.  doi: 10.1371/journal.pgen.1002548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pgen.1002548</ArticleId>
            <ArticleId IdType="pmc">PMC3305333</ArticleId>
            <ArticleId IdType="pubmed">22438815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Do C.B., Tung J.Y., Dorfman E., Kiefer A.K., Drabant E.M., Francke U., Mountain J.L., Goldman S.M., Tanner C.M., Langston J.W., et al.  Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson’s disease. PLoS Genet. 2011;7:e1002141.  doi: 10.1371/journal.pgen.1002141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pgen.1002141</ArticleId>
            <ArticleId IdType="pmc">PMC3121750</ArticleId>
            <ArticleId IdType="pubmed">21738487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>International Parkinson Disease Genomics Consortium. Nalls M.A., Plagnol V., Hernandez D.G., Sharma M., Sheerin U.M., Saad M., Simón-Sánchez J., Schulte C., Lesage S., et al.  Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: A meta-analysis of genome-wide association studies. Lancet. 2011;377:641–649.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3696507</ArticleId>
            <ArticleId IdType="pubmed">21292315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edwards T.L., Scott W.K., Almonte C., Burt A., Powell E.H., Beecham G.W., Wang L., Züchner S., Konidari I., Wang G., et al.  Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann. Hum. Genet. 2010;74:97–109. doi: 10.1111/j.1469-1809.2009.00560.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1469-1809.2009.00560.x</ArticleId>
            <ArticleId IdType="pmc">PMC2853717</ArticleId>
            <ArticleId IdType="pubmed">20070850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pankratz N., Wilk J.B., Latourelle J.C., DeStefano A.L., Halter C., Pugh E.W., Doheny K.F., Gusella J.F., Nichols W.C., Foroud T., et al.  Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum. Genet. 2009;124:593–605. doi: 10.1007/s00439-008-0582-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00439-008-0582-9</ArticleId>
            <ArticleId IdType="pmc">PMC2627511</ArticleId>
            <ArticleId IdType="pubmed">18985386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pankratz N., Beecham G.W., de Stefano A.L., Dawson T.M., Doheny K.F., Factor S.A., Hamza T.H., Hung A.Y., Hyman B.T., Ivinson A.J., et al.  Meta-analysis of Parkinson’s disease: Identification of a novel locus, RIT2. Ann. Neurol. 2012;71:370–384. doi: 10.1002/ana.22687.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.22687</ArticleId>
            <ArticleId IdType="pmc">PMC3354734</ArticleId>
            <ArticleId IdType="pubmed">22451204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simón-Sánchez J., van Hilten J.J., van de Warrenburg B., Post B., Berendse H.W., Arepalli S., Hernandez D.G., de Bie R.M., Velseboer D., Scheffer H., et al.  Genome-wide association study confirms extant PD risk loci among the Dutch. Eur. J. Hum. Genet. 2011;19:655–661. doi: 10.1038/ejhg.2010.254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ejhg.2010.254</ArticleId>
            <ArticleId IdType="pmc">PMC3110043</ArticleId>
            <ArticleId IdType="pubmed">21248740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X., Cheng R., Verbitsky M., Kisselev S., Browne A., Mejia-Sanatana H., Louis E.D., Cote L.J., Andrews H., Waters C., et al.  Genome-wide association study identifies candidate genes for Parkinson’s disease in an Ashkenazi Jewish population. BMC Med. Genet. 2011;12:104.  doi: 10.1186/1471-2350-12-104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2350-12-104</ArticleId>
            <ArticleId IdType="pmc">PMC3166909</ArticleId>
            <ArticleId IdType="pubmed">21812969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernandez D.G., Nalls M.A., Ylikotila P., Keller M., Hardy J.A., Majamaa K., Singleton A.B. Genome wide assessment of young onset Parkinson’s disease from Finland. PLoS ONE. 2012;7:e41859.  doi: 10.1371/journal.pone.0041859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0041859</ArticleId>
            <ArticleId IdType="pmc">PMC3404082</ArticleId>
            <ArticleId IdType="pubmed">22911860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foo J.N., Tan L.C., Irwan I.D., Au W.L., Low H.Q., Prakash K.M., Ahmad-Annuar A., Bei J., Chan A.Y., Chen C.M., et al.  Genome-wide association study of Parkinson’s disease in East Asians. Hum. Mol. Genet. 2016 doi: 10.1093/hmg/ddw379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddw379</ArticleId>
            <ArticleId IdType="pubmed">28011712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M., Mu H., Shang Z., Kang K., Lv H., Duan L., Li J., Chen X., Teng Y., Jiang Y., et al.  Genome-wide pathway-based association analysis identifies risk pathways associated with Parkinson’s disease. Neuroscience. 2017;340:398–410. doi: 10.1016/j.neuroscience.2016.11.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuroscience.2016.11.004</ArticleId>
            <ArticleId IdType="pubmed">27840232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nalls M.A., Pankratz N., Lill C.M., Do C.B., Hernandez D.G., Saad M., DeStefano A.L., Kara E., Bras J., Sharma M., et al.  Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat. Genet. 2014;46:989–993. doi: 10.1038/ng.3043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.3043</ArticleId>
            <ArticleId IdType="pmc">PMC4146673</ArticleId>
            <ArticleId IdType="pubmed">25064009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cen L., Xiao Y., Wei L., Mo M., Chen X., Li S., Yang X., Huang Q., Qu S., Pei Z., et al.  Association of DYRK1A polymorphisms with sporadic Parkinson’s disease in Chinese Han population. Neurosci. Lett. 2016;632:39–43. doi: 10.1016/j.neulet.2016.08.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neulet.2016.08.022</ArticleId>
            <ArticleId IdType="pubmed">27546826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Funayama M., Ohe K., Amo T., Furuya N., Yamaguchi J., Saiki S., Li Y., Ogaki K., Ando M., Yoshino H., et al.  CHCHD2 mutations in autosomal dominant late-onset Parkinson’s disease: A genome-wide linkage and sequencing study. Lancet Neurol. 2015;14:274–282. doi: 10.1016/S1474-4422(14)70266-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(14)70266-2</ArticleId>
            <ArticleId IdType="pubmed">25662902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohan M., Mellick G.D. Role of the VPS35 D620N mutation in Parkinson’s disease. Park. Relat. Disord. 2016 doi: 10.1016/j.parkreldis.2016.12.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.parkreldis.2016.12.001</ArticleId>
            <ArticleId IdType="pubmed">27964832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi C.H., Zhang S.Y., Yang Z.H., Yang J., Shang D.D., Mao C.Y., Liu H., Hou H.M., Shi MM., Wu J., et al.  A novel RAB39B gene mutation in X-linked juvenile Parkinsonism with basal ganglia calcification. Mov. Disord. 2016;31:1905–1909. doi: 10.1002/mds.26828.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.26828</ArticleId>
            <ArticleId IdType="pubmed">27943471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng H.X., Shi Y., Yang Y., Ahmeti K.B., Miller N., Huang C., Cheng L., Zhai H., Deng S., Nuytemans K., et al.  Identification of TMEM230 mutations in familial Parkinson’s disease. Nat. Genet. 2016;48:733–739. doi: 10.1038/ng.3589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.3589</ArticleId>
            <ArticleId IdType="pmc">PMC6047531</ArticleId>
            <ArticleId IdType="pubmed">27270108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng L., Wang L., Li N.N., Yu W.J., Sun X.Y., Li J.Y., Zhou D., Peng R. SNCA rs356182 variant increases risk of sporadic Parkinson’s disease in ethnic Chinese. J. Neurol. Sci. 2016;368:231–234. doi: 10.1016/j.jns.2016.07.032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2016.07.032</ArticleId>
            <ArticleId IdType="pubmed">27538639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Migdalska-Richards A., Schapira A.H. The relationship between glucocerebrosidase mutations and Parkinson disease. J. Neurochem. 2016;139:77–90. doi: 10.1111/jnc.13385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jnc.13385</ArticleId>
            <ArticleId IdType="pmc">PMC5111601</ArticleId>
            <ArticleId IdType="pubmed">26860875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrazza R., Cogo S., Melrose H., Bubacco L., Greggio E., Guella G., Civiero L., Plotegher N. LRRK2 deficiency impacts ceramide metabolism in brain. Biochem. Biophys. Res. Commun. 2016;478:1141–1146. doi: 10.1016/j.bbrc.2016.08.082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2016.08.082</ArticleId>
            <ArticleId IdType="pubmed">27539321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L., Mo M., Li G., Cen L., Wei L., Xiao Y., Chen X., Li S., Yang X., Qu S., et al.  The biomarkers of immune dysregulation and inflammation response in Parkinson disease. Transl. Neurodegener. 2016 doi: 10.1186/s40035-016-0063-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40035-016-0063-3</ArticleId>
            <ArticleId IdType="pmc">PMC5002148</ArticleId>
            <ArticleId IdType="pubmed">27570618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao J., Yu S., Zheng Y., Yang H., Zhang J. Oxidative Modification and Its Implications for the Neurodegeneration of Parkinson’s Disease. Mol. Neurobiol. 2017;54:1404–1418. doi: 10.1007/s12035-016-9743-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12035-016-9743-3</ArticleId>
            <ArticleId IdType="pubmed">26843115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleinknecht A., Popova B., Lázaro D.F., Pinho R., Valerius O., Outeiro T.F., Braus G.H. C-Terminal Tyrosine Residue Modifications Modulate the Protective Phosphorylation of Serine 129 of α-Synuclein in a Yeast Model of Parkinson’s Disease. PLoS Genet. 2016;12:e1006098.  doi: 10.1371/journal.pgen.1006098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pgen.1006098</ArticleId>
            <ArticleId IdType="pmc">PMC4920419</ArticleId>
            <ArticleId IdType="pubmed">27341336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bang Y., Kim K.S., Seol W., Choi H.J. LRRK2 interferes with aggresome formation for autophagic clearance. Mol. Cell. Neurosci. 2016;75:71–80. doi: 10.1016/j.mcn.2016.06.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mcn.2016.06.007</ArticleId>
            <ArticleId IdType="pubmed">27364102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C.W., Hang L., Yao T.P., Lim K.L. Parkin Regulation and Neurodegenerative Disorders. Front. Aging Neurosci. 2016;7:248. doi: 10.3389/fnagi.2015.00248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnagi.2015.00248</ArticleId>
            <ArticleId IdType="pmc">PMC4709595</ArticleId>
            <ArticleId IdType="pubmed">26793099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bose A., Beal M.F. Mitochondrial dysfunction in Parkinson’s disease. J. Neurochem. 2016;1802:29–44. doi: 10.1111/jnc.13731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jnc.13731</ArticleId>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buhlman L.M. Parkin loss-of-function pathology: Premature neuronal senescence induced by high levels of reactive oxygen species? Mech. Ageing Dev. 2016;161:112–120. doi: 10.1016/j.mad.2016.06.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mad.2016.06.008</ArticleId>
            <ArticleId IdType="pubmed">27374431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Z.D., Sathiyamoorthy S., Angeles D.C., Tan E.K. Linking F-box protein 7 and parkin to neuronal degeneration in Parkinson’s disease (PD) Mol. Brain. 2016;9:41. doi: 10.1186/s13041-016-0218-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13041-016-0218-2</ArticleId>
            <ArticleId IdType="pmc">PMC4835861</ArticleId>
            <ArticleId IdType="pubmed">27090516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teixeira F.R., Randle S.J., Patel S.P., Mevissen T.E., Zenkeviciute G., Koide T., Komander D., Laman H. Gsk3β and Tomm20 are substrates of the SCFFbxo7/PARK15 ubiquitin ligase associated with Parkinson’s disease. Biochem. J. 2016;473:3563–3580. doi: 10.1042/BCJ20160387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BCJ20160387</ArticleId>
            <ArticleId IdType="pmc">PMC5260939</ArticleId>
            <ArticleId IdType="pubmed">27503909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saito Y., Akazawa-Ogawa Y., Matsumura A., Saigoh K., Itoh S., Sutou K., Kobayashi M., Mita Y., Shichiri M., Hisahara S., et al.  Oxidation and interaction of DJ-1 with 20S proteasome in the erythrocytes of early stage Parkinson’s disease patients. Sci. Rep. 2016;6 doi: 10.1038/srep30793.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep30793</ArticleId>
            <ArticleId IdType="pmc">PMC4965792</ArticleId>
            <ArticleId IdType="pubmed">27470541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mo M.S., Huang W., Sun C.C., Zhang L.M., Cen L., Xiao Y.S., Li G.F., Yang X.L., Qu S.G., Xu P.Y. Association Analysis of Proteasome Subunits and Transporter Associated with Antigen Processing on Chinese Patients with Parkinson’s Disease. Chin. Med. J. 2016;129:1053–1058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4852672</ArticleId>
            <ArticleId IdType="pubmed">27098790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pihlstrøm L., Berge V., Rengmark A., Toft M. Parkinson’s disease correlates with promoter methylation in the α-synuclein gene. Mov. Disord. 2015;30:577–580. doi: 10.1002/mds.26073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.26073</ArticleId>
            <ArticleId IdType="pubmed">25545759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ammal Kaidery N., Tarannum S., Thomas B. Epigenetic landscape of Parkinson’s disease: Emerging role in disease mechanisms and therapeutic modalities. Neurotherapeutics. 2013;10:698–708. doi: 10.1007/s13311-013-0211-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13311-013-0211-8</ArticleId>
            <ArticleId IdType="pmc">PMC3805874</ArticleId>
            <ArticleId IdType="pubmed">24030213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masliah E., Dumaop W., Galasko D., Desplats P. Distinctive patterns of DNA methylation associated with Parkinson disease: Identification of concordant epigenetic changes in brain and peripheral blood leukocytes. Epigenetics. 2013;8:1030–1038. doi: 10.4161/epi.25865.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/epi.25865</ArticleId>
            <ArticleId IdType="pmc">PMC3891683</ArticleId>
            <ArticleId IdType="pubmed">23907097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore K., McKnight A.J., Craig D., O’Neill F. Epigenome-wide association study for Parkinson’s disease. Neuromol. Med. 2014;16:845–855. doi: 10.1007/s12017-014-8332-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12017-014-8332-8</ArticleId>
            <ArticleId IdType="pubmed">25304910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cacabelos R., Torrellas C., Carril J.C., Aliev G., Teijido O. Epigenomics and proteomics of brain disorders. Curr. Genom. 2017 in press.</Citation>
        </Reference>
        <Reference>
          <Citation>Mo M., Xiao Y., Huang S., Cen L., Chen X., Zhang L., Luo Q., Li S., Yang X., Lin X., et al.  MicroRNA expressing profiles in A53T mutant alpha-synuclein transgenic mice and Parkinsonian. Oncotarget. 2016 doi: 10.18632/oncotarget.13905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.13905</ArticleId>
            <ArticleId IdType="pmc">PMC5352072</ArticleId>
            <ArticleId IdType="pubmed">27965467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oertel W., Schulz J.B. Current and experimental treatments of Parkinson disease: A guide for neuroscientists. J. Neurochem. 2016;139:325–337. doi: 10.1111/jnc.13750.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jnc.13750</ArticleId>
            <ArticleId IdType="pubmed">27577098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pahwa R., Lyons K.E. Levodopa-related wearing-off in Parkinson’s disease: Identification and management. Curr. Med. Res. Opin. 2009;25:841–849. doi: 10.1185/03007990902779319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1185/03007990902779319</ArticleId>
            <ArticleId IdType="pubmed">19228103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhidayasiri R., Hattori N., Jeon B., Chen R.S., Lee M.K., Bajwa J.A., Mok V.C., Zhang B., Syamsudin T., Tan L.C., et al.  Asian perspectives on the recognition and management of levodopa ‘wearing-off’ in Parkinson’s disease. Expert Rev. Neurother. 2015;15:1285–1297. doi: 10.1586/14737175.2015.1088783.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/14737175.2015.1088783</ArticleId>
            <ArticleId IdType="pubmed">26390066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haaxma C.A., Horstink M.W., Zijlmans J.C., Lemmens W.A., Bloem B.R., Borm G.F. Risk of disabling response fluctuations and dyskinesias for dopamine agonists versus Levodopa in Parkinson’s disease. J. Parkinsons Dis. 2015;5:847–853. doi: 10.3233/JPD-150532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JPD-150532</ArticleId>
            <ArticleId IdType="pubmed">26444087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rascol O., Perez-Lloret S., Ferreira J.J. New treatments for levodopa-induced motor complications. Mov. Disord. 2015;30:1451–1460. doi: 10.1002/mds.26362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.26362</ArticleId>
            <ArticleId IdType="pubmed">26293004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stowe R., Ives N., Clarke C.E., Deane K., van Hilten J., Wheatley K., Gray R., Handley K., Furmston A. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst. Rev. 2010;7:CD007166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20614454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lertxundi U., Isla A., Solinis M.A., Domingo-Echaburu S., Hernandez R., Peral-Aguirregoitia J., Medrano J. Anticholinergic burden in Parkinson’s disease inpatients. Eur. J. Clin. Pharmacol. 2015;71:1271–1277. doi: 10.1007/s00228-015-1919-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00228-015-1919-7</ArticleId>
            <ArticleId IdType="pubmed">26254777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Owolabi L.F., Samaila A.A., Sunmonu T. Gastrointestinal complications in newly diagnosed Parkinson’s disease: A case-control study. Trop. Gastroenterol. 2014;35:227–231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26349167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knudsen K., Krogh K., Østergaard K., Borghammer P. Constipation in Parkinson’s disease: Subjective symptoms, objective markers, and new perspectives. Mov. Disord. 2017;32:94–105. doi: 10.1002/mds.26866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.26866</ArticleId>
            <ArticleId IdType="pubmed">27873359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tran T., Brophy J.M., Suissa S., Renoux C. Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson’s Disease: A Systematic Review of Observational Studies. CNS Drugs. 2015;29:985–998. doi: 10.1007/s40263-015-0293-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40263-015-0293-4</ArticleId>
            <ArticleId IdType="pubmed">26585874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki M., Nakamura T., Hirayama M., Ueda M., Katsuno M., Sobue G. Cardiac parasympathetic dysfunction in the early phase of Parkinson’s disease. J. Neurol. 2016;264:333–340. doi: 10.1007/s00415-016-8348-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-016-8348-0</ArticleId>
            <ArticleId IdType="pubmed">27900499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barone P., Santangelo G., Amboni M., Pellecchia M.T., Vitale C. Pisa syndrome in Parkinson’s disease and Parkinsonism: Clinical features, pathophysiology, and treatment. Lancet Neurol. 2016;15:1063–1074. doi: 10.1016/S1474-4422(16)30173-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(16)30173-9</ArticleId>
            <ArticleId IdType="pubmed">27571158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altmann V., Schumacher-Schuh A.F., Rieck M., Callegari-Jacques S.M., Rieder C.R., Hutz M.H. Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson’s disease. Pharmacogenomics. 2016;17:481–488. doi: 10.2217/pgs.15.183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/pgs.15.183</ArticleId>
            <ArticleId IdType="pubmed">27019953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiménez-Jiménez F.J., Alonso-Navarro H., García-Martín E., Agúndez J.A. Advances in understanding genomic markers and pharmacogenetics of Parkinson’s disease. Expert Opin. Drug Metab. Toxicol. 2016;12:433–448. doi: 10.1517/17425255.2016.1158250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/17425255.2016.1158250</ArticleId>
            <ArticleId IdType="pubmed">26910127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurzawski M., Białecka M., Droździk M. Pharmacogenetic considerations in the treatment of Parkinson’s disease. Neurodegener. Dis. Manag. 2015;5:27–35. doi: 10.2217/nmt.14.38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/nmt.14.38</ArticleId>
            <ArticleId IdType="pubmed">25711452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schumacher-Schuh A.F., Rieder C.R., Hutz M.H. Parkinson’s disease pharmacogenomics: New findings and perspectives. Pharmacogenomics. 2014;15:1253–1271. doi: 10.2217/pgs.14.93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/pgs.14.93</ArticleId>
            <ArticleId IdType="pubmed">25141900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rieck M., Schumacher-Schuh A.F., Callegari-Jacques S.M., Altmann V., Schneider Medeiros M., Hutz M.H. Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson’s disease patients? Pharmacogenomics. 2015;16:573–582. doi: 10.2217/pgs.15.23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/pgs.15.23</ArticleId>
            <ArticleId IdType="pubmed">25872644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schumacher-Schuh A.F., Altmann V., Rieck M., Tovo-Rodrigues L., Monte T.L., Callegari-Jacques S.M., Medeiros M.S., Rieder C.R., Hutz M.H. Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson’s disease patients. Pharmacogenom. J. 2014;14:289–294. doi: 10.1038/tpj.2013.37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/tpj.2013.37</ArticleId>
            <ArticleId IdType="pubmed">24126708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rieck M., Schumacher-Schuh A.F., Altmann V., Francisconi C.L., Fagundes P.T., Monte T.L., Callegari-Jacques S.M., Rieder C.R., Hutz M.H. DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson’s disease patients. Pharmacogenomics. 2012;13:1701–1710. doi: 10.2217/pgs.12.149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/pgs.12.149</ArticleId>
            <ArticleId IdType="pubmed">23171335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moreau C., Meguig S., Corvol J.C., Labreuche J., Vasseur F., Duhamel A., Delval A., Bardyn T., Devedjian J.C., Rouaix N., et al.  Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson’s disease. Brain. 2015;138:1271–1283. doi: 10.1093/brain/awv063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awv063</ArticleId>
            <ArticleId IdType="pmc">PMC5963414</ArticleId>
            <ArticleId IdType="pubmed">25805645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed S.S., Husain R.S., Kumar S., Ramakrishnan V. Association between MDR1 gene polymorphisms and Parkinson’s disease in Asian and Caucasian populations: A meta-analysis. J. Neurol. Sci. 2016;368:255–262. doi: 10.1016/j.jns.2016.07.041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2016.07.041</ArticleId>
            <ArticleId IdType="pubmed">27538645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lohr K.-M., Masoud S.T., Salahpour A., Miller G.W. Membrane transporters as mediators of synaptic dopamine dynamics: Implications for disease. Eur. J. Neurosci. 2017;45:20–33. doi: 10.1111/ejn.13357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ejn.13357</ArticleId>
            <ArticleId IdType="pmc">PMC5209277</ArticleId>
            <ArticleId IdType="pubmed">27520881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim H.J., Jeon B., Chung S.J. Professional ethics in complementary and alternative medicines in management of Parkinson’s disease. J. Park. Dis. 2016;6:675–683. doi: 10.3233/JPD-160890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JPD-160890</ArticleId>
            <ArticleId IdType="pmc">PMC5088405</ArticleId>
            <ArticleId IdType="pubmed">27589539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carrera I., Fernández-Novoa L., Sampedro C., Cacabelos R. Neuroprotective effect of atremorine in an experimental model of Parkinson’s disease. Curr. Pharm. Des. 2017 doi: 10.2174/1381612823666170210143530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1381612823666170210143530</ArticleId>
            <ArticleId IdType="pubmed">28190394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cacabelos R. Bioactive Extract Obtained from Vicia Faba and Its Use in the Treatment and/or Prevention of Neurodegenerative Diseases. EP16382138. European Patent. 2016 Mar 29;</Citation>
        </Reference>
        <Reference>
          <Citation>Goodarzi Z., Mele B., Guo A., Hanson H., Jette N., Patten S., Pringsheim T., Holroyd-Leduc J. Guidelines for dementia or Parkinson’s disease with depression or anxiety: A systemic review. BMC Neurol. 2016;16:244.  doi: 10.1186/s12883-016-0754-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12883-016-0754-5</ArticleId>
            <ArticleId IdType="pmc">PMC5124305</ArticleId>
            <ArticleId IdType="pubmed">27887589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cavalcanti J.R., Pontes A.L., Fiuza F.P., Silva K.D., Guzen F.P., Lucena E.E., Nascimento-Júnior E.S., Cavalcante J.C., Costa M.S., Engelberth R.C., et al.  Nuclear organization of the substantia nigra, ventral tegmental area and retrorubral field of the common marmoset (Callithrix jacchus): A cytoarchitectonic and TH-immunohistochemistry study. J. Chem. Neuroanat. 2016;77:100–109. doi: 10.1016/j.jchemneu.2016.05.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jchemneu.2016.05.010</ArticleId>
            <ArticleId IdType="pubmed">27292410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sulzer D., Cragg S.J., Rice M.E. Striatal dopamine neurotransmission: Regulation of release and uptake. Basal Ganglia. 2016;6:123–148. doi: 10.1016/j.baga.2016.02.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.baga.2016.02.001</ArticleId>
            <ArticleId IdType="pmc">PMC4850498</ArticleId>
            <ArticleId IdType="pubmed">27141430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chandler D.J., Waterhouse B.D., Gao W.J. New perspectives on catecholaminergic regulation of executive circuits: Evidence for independent modulation of prefrontal functions by midbrain dopaminergic and noradrenergic neurons. Front. Neural Circuits. 2014;8:53. doi: 10.3389/fncir.2014.00053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fncir.2014.00053</ArticleId>
            <ArticleId IdType="pmc">PMC4033238</ArticleId>
            <ArticleId IdType="pubmed">24904299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xing B., Li Y.C., Gao W.J. Norepinephrine versus dopamine and their interaction in modulating synaptic function in the prefrontal cortex. Brain Res. 2016;1641:217–233. doi: 10.1016/j.brainres.2016.01.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainres.2016.01.005</ArticleId>
            <ArticleId IdType="pmc">PMC4879059</ArticleId>
            <ArticleId IdType="pubmed">26790349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wakamatsu K., Tabuchi K., Ojika M., Zucca F.A., Zecca L., Ito S. Norepinephrine and its metabolites are involved in the synthesis of neuromelanin derived from the locus coeruleus. J. Neurochem. 2015;135:768–776. doi: 10.1111/jnc.13237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jnc.13237</ArticleId>
            <ArticleId IdType="pmc">PMC5014224</ArticleId>
            <ArticleId IdType="pubmed">26156066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buddhala C., Loftin S.K., Kuley B.M., Cairns N.J., Campbell M.C., Perlmutter J.S., Joel S. Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease. Ann. Clin. Transl. Neurol. 2015;2:949–959. doi: 10.1002/acn3.246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acn3.246</ArticleId>
            <ArticleId IdType="pmc">PMC4603378</ArticleId>
            <ArticleId IdType="pubmed">26478895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jellinger K.A. Post mortem studies in Parkinson’s disease—Is it possible to detect brain areas for specific symptoms? J. Neural Transm. Suppl. 1999;56:1–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10370901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grouleff J., Ladefoged L.K., Koldsø H., Schiøtt B. Monoamine transporters: Insights from molecular dynamics simulations. Front. Pharmacol. 2015;6:235. doi: 10.3389/fphar.2015.00235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2015.00235</ArticleId>
            <ArticleId IdType="pmc">PMC4607855</ArticleId>
            <ArticleId IdType="pubmed">26528185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lohr K.M., Bernstein A.I., Stout K.A., Dunn A.R., Lazo C.R., Alter S.P., Wang M., Li Y., Fan X., Hess E.J., et al.  Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proc. Natl. Acad. Sci. USA. 2014;111:9977–9982. doi: 10.1073/pnas.1402134111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1402134111</ArticleId>
            <ArticleId IdType="pmc">PMC4103325</ArticleId>
            <ArticleId IdType="pubmed">24979780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagatsu T., Nagatsu I. Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson’s disease (PD): Historical overview and future prospects. J. Neural Transm. 2016;123:1255–1278. doi: 10.1007/s00702-016-1596-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00702-016-1596-4</ArticleId>
            <ArticleId IdType="pubmed">27491309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conti M.M., Meadows S.M., Melikhov-Sosin M., Lindenbach D., Hallmark J., Werner D.F. Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats. Neuropharmacology. 2016;110:125–134. doi: 10.1016/j.neuropharm.2016.07.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2016.07.025</ArticleId>
            <ArticleId IdType="pubmed">27452719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mittal R., Debs L.H., Patel A.P., Nguyen D., Patel K., O’Connor G., Grati M., Mittal J., Yan D., Eshraghi A.A., et al.  Neurotransmitters: The Critical Modulators Regulating Gut-Brain Axis. J. Cell. Physiol. 2016 doi: 10.1002/jcp.25518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.25518</ArticleId>
            <ArticleId IdType="pmc">PMC5772764</ArticleId>
            <ArticleId IdType="pubmed">27512962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cenci M.A. Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications. Front. Neurol. 2014;5:242. doi: 10.3389/fneur.2014.00242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2014.00242</ArticleId>
            <ArticleId IdType="pmc">PMC4266027</ArticleId>
            <ArticleId IdType="pubmed">25566170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain S., Goldstein D.S. Cardiovascular dysautonomia in Parkinson disease: From pathophysiology to pathogenesis. Neurobiol. Dis. 2012;46:572–580. doi: 10.1016/j.nbd.2011.10.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nbd.2011.10.025</ArticleId>
            <ArticleId IdType="pmc">PMC3299874</ArticleId>
            <ArticleId IdType="pubmed">22094370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olanow C.W. Levodopa: Effect on cell death and the natural history of Parkinson’s disease. Mov. Disord. 2015;30:37–44. doi: 10.1002/mds.26119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.26119</ArticleId>
            <ArticleId IdType="pubmed">25502620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagatsu T., Sawada M. Biochemistry of postmortem brains in Parkinson’s disease: Historical overview and future prospects. J. Neural Transm. Suppl. 2007;72:113–120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17982884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vermeiren Y., de Deyn P.P. Targeting the norepinephrinergic system in Parkinson’s disease and related disorders: The locus coeruleus story. Neurochem. Int. 2016;102:22–32. doi: 10.1016/j.neuint.2016.11.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuint.2016.11.009</ArticleId>
            <ArticleId IdType="pubmed">27899296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feinstein D.L., Kalinin S., Braun D. Causes, consequences, and cures for neuroinflammation mediated via the locus coeruleus: Noradrenergic signaling system. J. Neurochem. 2016;139:154–178. doi: 10.1111/jnc.13447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jnc.13447</ArticleId>
            <ArticleId IdType="pubmed">26968403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braun D., Madrigal J.L., Feinstein D.L. Noradrenergic regulation of glial activation: Molecular mechanisms and therapeutic implications. Curr. Neuropharmacol. 2014;12:342–352. doi: 10.2174/1570159X12666140828220938.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1570159X12666140828220938</ArticleId>
            <ArticleId IdType="pmc">PMC4207074</ArticleId>
            <ArticleId IdType="pubmed">25342942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Espay A.J., LeWitt P.A., Kaufmann H. Norepinephrine deficiency in Parkinson’s disease: The case for noradrenergic enhancement. Mov. Disord. 2014;29:1710–1719. doi: 10.1002/mds.26048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.26048</ArticleId>
            <ArticleId IdType="pubmed">25297066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rommelfanger K.S., Weinshenker D. Norepinephrine: The redheaded stepchild of Parkinson’s disease. Biochem. Pharmacol. 2007;74:177–190. doi: 10.1016/j.bcp.2007.01.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2007.01.036</ArticleId>
            <ArticleId IdType="pubmed">17416354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mejias-Aponte C.A. Specificity and impact of adrenergic projections to the midbrain dopamine system. Brain Res. 2016;1641:258–273. doi: 10.1016/j.brainres.2016.01.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainres.2016.01.036</ArticleId>
            <ArticleId IdType="pmc">PMC4879068</ArticleId>
            <ArticleId IdType="pubmed">26820641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aziz N.A., Pijl H., Frölich M., Roelfsema F., Roos R.A. Diurnal secretion profiles of growth hormone, thyrotrophin and prolactin in Parkinson’s disease. J. Neuroendocrinol. 2011;23:519–524. doi: 10.1111/j.1365-2826.2011.02134.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2826.2011.02134.x</ArticleId>
            <ArticleId IdType="pubmed">21466597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willis G.L. Parkinson’s disease as a neuroendocrine disorder of circadian function: Dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process. Rev. Neurosci. 2008;19:245–316. doi: 10.1515/REVNEURO.2008.19.4-5.245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1515/REVNEURO.2008.19.4-5.245</ArticleId>
            <ArticleId IdType="pubmed">19145986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schaefer S., Vogt T., Nowak T., Kann P.H. German KIMS board. Pituitary function and the somatotrophic system in patients with idiopathic Parkinson’s disease under chronic dopaminergic therapy. J. Neuroendocrinol. 2008;20:104–109. doi: 10.1111/j.1365-2826.2007.01622.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2826.2007.01622.x</ArticleId>
            <ArticleId IdType="pubmed">18081558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gruszka A., Ren S.G., Dong J., Culler M.D., Melmed S. Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology. 2007;148:6107–6114. doi: 10.1210/en.2007-0378.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/en.2007-0378</ArticleId>
            <ArticleId IdType="pubmed">17656461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wells S., Murphy D. Transgenic studies on the regulation of the anterior pituitary gland function by the hypothalamus. Front. Neuroendocrinol. 2003;24:11–26. doi: 10.1016/S0091-3022(02)00103-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0091-3022(02)00103-6</ArticleId>
            <ArticleId IdType="pubmed">12609498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin J., Hara S., Sawai K., Fülöp F., Nagy G.M., Hashizume T. Effects of hypothalamic dopamine (DA) on salsolinol (SAL)-induced prolactin (PRL) secretion in male goats. Anim. Sci. J. 2014;85:461–467. doi: 10.1111/asj.12157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/asj.12157</ArticleId>
            <ArticleId IdType="pubmed">24329779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nitkowska M., Tomasiuk R., Czyżyk M., Friedman A. Prolactin and sex hormones levels in males with Parkinson’s disease. Acta Neurol. Scand. 2015;131:411–416. doi: 10.1111/ane.12334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ane.12334</ArticleId>
            <ArticleId IdType="pubmed">25399742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimber J., Watson L., Mathias C.J. Neuroendocrine responses to levodopa in multiple system atrophy (MSA) Mov. Disord. 1999;14:981–987. doi: 10.1002/1531-8257(199911)14:6&lt;981::AID-MDS1011&gt;3.0.CO;2-W.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1531-8257(199911)14:6&lt;981::AID-MDS1011&gt;3.0.CO;2-W</ArticleId>
            <ArticleId IdType="pubmed">10584673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimber J.R., Watson L., Mathias C.J. Distinction of idiopathic Parkinson’s disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine. Lancet. 1997;349:1877–1881. doi: 10.1016/S0140-6736(96)10168-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(96)10168-9</ArticleId>
            <ArticleId IdType="pubmed">9217760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winkler A.S., Landau S., Chaudhuri K.R. Serum prolactin levels in Parkinson’s disease and multiple system atrophy. Clin. Auton. Res. 2002;12:393–398. doi: 10.1007/s10286-002-0025-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10286-002-0025-y</ArticleId>
            <ArticleId IdType="pubmed">12420085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogawa A., Kanazawa M., Takayanagi M., Kitani Y., Shintaku H., Kohno Y. A case of 6-pyruvoyl-tetrahydropterin synthase deficiency demonstrates a more significant correlation of l-Dopa dosage with serum prolactin levels than CSF homovanillic acid levels. Brain Dev. 2008;30:82–85. doi: 10.1016/j.braindev.2007.05.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.braindev.2007.05.011</ArticleId>
            <ArticleId IdType="pubmed">17590551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Müller T., Welnic J., Woitalla D., Muhlack S. Endurance exercise modulates levodopa induced growth hormone release in patients with Parkinson’s disease. Neurosci. Lett. 2007;422:119–122. doi: 10.1016/j.neulet.2007.06.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neulet.2007.06.008</ArticleId>
            <ArticleId IdType="pubmed">17590511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kasuya E., Yayou K., Sutoh M. L-DOPA attenuates prolactin secretion in response to isolation stress in Holstein steers. Anim. Sci. J. 2013;84:562–568. doi: 10.1111/asj.12037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/asj.12037</ArticleId>
            <ArticleId IdType="pubmed">23607456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Székács D., Bodnár I., Mravec B., Kvetnansky R., Vizi E.S., Nagy G.M., Fekete M.I. The peripheral noradrenergic terminal as possible site of action of salsolinol as prolactoliberin. Neurochem. Int. 2007;50:427–434. doi: 10.1016/j.neuint.2006.10.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuint.2006.10.001</ArticleId>
            <ArticleId IdType="pubmed">17141375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levandis G., Balestra B., Siani F., Rizzo V., Ghezzi C., Ambrosi G. Response of colonic motility to dopaminergic stimulation is subverted in rats with nigrostriatal lesion: Relevance to gastrointestinal dysfunctions in Parkinson’s disease. Neurogastroenterol. Motil. 2015;27:1783–1795. doi: 10.1111/nmo.12691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nmo.12691</ArticleId>
            <ArticleId IdType="pubmed">26433214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cacabelos R. Biochemical changes and cardiovascular function in Parkinson’s disease. Clin. Med. Biochem. 2016;2:2. doi: 10.4172/2471-2663.1000e102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4172/2471-2663.1000e102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Z., Du X., Xu H., Xie J., Jiang H. Lesion of medullary catecholaminergic neurons is associated with cardiovascular dysfunction in rotenone-induced Parkinson’s disease rats. Eur. J. Neurosci. 2015;42:2346–2355. doi: 10.1111/ejn.13012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ejn.13012</ArticleId>
            <ArticleId IdType="pubmed">26153521</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
